Get the Stockscreener App
53.84
1.22%
-0.745
Sanofi Adr stock is traded at $53.84, with a volume of 1.37M.
It is down -1.22% in the last 24 hours and up +3.74% over the past month.
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
See More
Previous Close:
$54.59
Open:
$54.74
24h Volume:
1.37M
Relative Volume:
0.52
Market Cap:
$128.86B
Revenue:
$48.62B
Net Income/Loss:
$6.80B
P/E Ratio:
19.20
EPS:
2.8038
Net Cash Flow:
$7.62B
1W Performance:
+0.38%
1M Performance:
+3.74%
6M Performance:
+5.20%
1Y Performance:
+9.31%
1-Day Range:
$53.83
$54.75
1-Week Range:
$53.92
$55.73
52-Week Range:
$45.80
$60.12
Sanofi Adr Stock (SNY) Company Profile
Name
Sanofi Adr
Sector
Industry
Phone
-
Address
-
Compare SNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
53.83 | 128.86B | 48.62B | 6.80B | 7.62B | 2.8038 |
|
LLY
Lilly Eli Co
|
783.38 | 737.81B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.17 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
187.23 | 340.25B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
66.61 | 277.97B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
111.98 | 222.45B | 53.22B | 12.86B | 14.85B | 6.39 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Mar-21-25 | Initiated | Goldman | Neutral |
| Jan-30-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Jul-26-24 | Reiterated | Argus | Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-05-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-30-23 | Downgrade | Stifel | Buy → Hold |
| Sep-06-23 | Upgrade | Berenberg | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-28-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-27-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-13-22 | Resumed | Morgan Stanley | Overweight |
| Aug-12-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-09-22 | Downgrade | UBS | Buy → Neutral |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Sep-27-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-15-21 | Initiated | Deutsche Bank | Sell |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Mar-17-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-11-20 | Upgrade | Goldman | Neutral → Buy |
| Feb-11-20 | Initiated | SVB Leerink | Mkt Perform |
| Jan-06-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-20-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-03-19 | Initiated | Bernstein | Outperform |
| Aug-14-19 | Upgrade | UBS | Neutral → Buy |
| Dec-11-18 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-10-18 | Upgrade | Citigroup | Neutral → Buy |
| Mar-23-18 | Upgrade | Liberum | Hold → Buy |
| Jan-23-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-06-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-01-17 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Nov-15-17 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-30-17 | Upgrade | HSBC Securities | Reduce → Hold |
View All
Sanofi Adr Stock (SNY) Latest News
iRhythm Technologies Inc (IRTC) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
WLK’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
BIDU’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
A Tale of Resilience: Sanofi ADR Amid Stock Market Turbulence - investchronicle.com
Company’s Banking Stock: Dissecting a 40.08% Quarterly Revenue Decline Amid Growth - investchronicle.com
Trip.com Group Ltd ADR (TCOM) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
CYTK’s 2023 Market Dance: Down -21.41% – Time to Invest? - investchronicle.com
CIG’s Market Whiplash: 8.19% YTD Rise, 9.30% Rise in 30 Days - investchronicle.com
LX’s 2023 Market Dance: Up 43.28% – Time to Invest? - investchronicle.com
Terex Corp (TEX) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Behind Cytosorbents Corp’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
Companhia Siderurgica Nacional ADR (SID) Stock: From Low to High in 52 Weeks - investchronicle.com
The Future of EVgo Inc: Analyzing EVGO - investchronicle.com
NVS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Unilever plc ADR: Rising -3.90% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Adaptive Biotechnologies Corp (ADPT) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Futu Holdings Ltd ADR (FUTU) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
Stryker Corp (SYK) Stock: Navigating a Year of Volatility - investchronicle.com
Viking Holdings Ltd’s Banking’s 100-Day Moving Average at 44.43: Will the Stock Break Through? - investchronicle.com
Sandisk Corp (SNDK) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
LSCC: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
LATAM Airlines Group S.A. ADR’s Banking’s 100-Day Moving Average at 29.99: Will the Stock Break Through? - investchronicle.com
DUOL’s 2023 Market Dance: Up 43.43% – Time to Invest? - investchronicle.com
PLRZ Stock: Exploring Polyrizon Ltd’s Growth - investchronicle.com
Sumitomo Mitsui Financial Group Inc ADR (SMFG) Stock: A Year of Market Movement, Down and Up - investchronicle.com
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Mars 2025 - GlobeNewswire Inc.
Vipshop Holdings Ltd ADR Inc. (VIPS) Price Performance: The Role of Supply and Demand - investchronicle.com
CNMD’s 52-Week Rollercoaster: From $46.00 to $78.58 – What’s Next for Investors? - investchronicle.com
AngloGold Ashanti Plc (AU) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
UDMY: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Hologic, Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
Viavi Solutions Inc (VIAV) Stock: From Low to High in 52 Weeks - investchronicle.com
PRU’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
ModivCare Inc (MODV) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Uncovering the Potential of Idexx Laboratories, Inc (IDXX) Stock - investchronicle.com
Mimedx Group Inc (MDXG) Stock: A Year of Market Fluctuations - investchronicle.com
AMRX’s Financial Health: Exploring Amneal Pharmaceuticals Inc’s Debt-to-Equity Ratio of 1.79 - investchronicle.com
Childrens Place Inc Inc. (PLCE) Price Performance: A Fundamental Analysis Perspective - investchronicle.com
Leonardo DRS Inc (DRS) Stock: Navigating Drops and Gains - investchronicle.com
Stocks With Rising Relative Price Strength: Smith & Nephew ADR - inkl
Stocks With Rising Relative Strength: Belden - inkl
ZTO Express [Cayman] Inc ADR [ZTO] is -2.81% lower this YTD. Is it still time to buy? - dbtnews.com
For Sanofi ADR [SNY], Analyst sees a rise to $65. What next? - dbtnews.com
MaxLinear Inc [MXL] Stock trading around $9.65 per share: What’s Next? - dbtnews.com
European Drug Giants Report. But Only One Beats Sales Views. - Investor's Business Daily
There is no doubt that Sanofi ADR (SNY) ticks all the boxes. - Sete News
Sanofi ADR earnings beat by $0.12, revenue fell short of estimates - Investing.com Canada
Views of Wall Street’s Leading Experts on TIM SA ADR - Sete News
Potential Price Increase for RELX Plc ADR (RELX) After Recent Insider Activity - knoxdaily.com
SPR’s latest rating updates from top analysts. - knoxdaily.com
Analysts review Sanofi ADR’s rating - knoxdaily.com
Sanofi Adr Stock (SNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):